Rephonic
Artwork for BiotechTV

BiotechTV - News

BiotechTV
FDA
Biotech
Clinical Trials
Alzheimer's Disease
Car-T Therapy
Obesity
Biotechnology
Oncology
Parkinson's Disease
Immunology
Breast Cancer
Gene Therapy
Multiple Myeloma
Artificial Intelligence
Mergers and Acquisitions
Takeda
TYK2
Biotech Industry
Rare Disease
Abivax

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

PublishesDailyEpisodes426Foundeda year ago
Number of ListenersCategories
ScienceLife Sciences

Listen to this Podcast

Artwork for BiotechTV

Latest Episodes

Philip Astley-Starke describes the timeline of development of this oncolytic immunotherapy, his impression of FDA's review process and decisions around it, and the status of where the treatment stands today.

CSO Robert Allen describes Invivyd's approach and why antibodies can be a good approach, especially as it relates to being resistant to viral evolution. He walks us through the science and some potential use cases.

Co-Founder & CEO Michel Maharbiz describes the idea behind this brain-computer interface (BCI), which is not yet in human trials. While cautioning that much work and learning lies ahead, he sees the possibility that such a system could also improve a... more

He describes his work in tropical disease, and how climate change has been elevating it in areas like the Gulf Coast of the United States. Plus, the importance of elevating scientists, what he has found works best for communicating with the public, a... more

Key Facts

Accepts Guests
Accepts Sponsors
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Biotech Hangout
Biotech HangoutDaphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more

Recent Guests

Errik Anderson
Founder and CEO of Alloy Therapeutics
Alloy Therapeutics
Episode: Alloy Therapeutics announced a deal with Biogen today to help them discover antisense therapeutics using Alloy's ASO platform. Alloy Founder & CEO Errik Anderson fills us in at the company's R&D Day.
Ian Smith
Director and CEO, Stoke Therapeutics
Stoke Therapeutics
Episode: The new CEO of Stoke Therapeutics, Ian Smith, discusses Stoke Therapeutics' Dravet syndrome therapy, which caught much attention after publishing phase 1/2 data in NEJM last month
Tom Miller
CEO and co-founder of Iambic Therapeutics
Iambic Therapeutics
Episode: Iambic's CEO Tom Miller discusses the company's approach to AI drug discovery (hint: it's way more than protein folding), and highlights the company's clinical HER2 program, and two others on the way
Jack Dent
Co-founder of Chai Discovery
Chai Discovery
Episode: Already this year Chai Discovery has raised a $130M series B and struck a discovery partnership with Eli Lilly - Co-Founder Jack Dent describes how Chai is using AI to design antibodies
Will West
Co-founder and Chief Executive, CellCentric
CellCentric
Episode: CellCentric has kicked off dosing of its first registration-supporting study for the oral p300/CBP inhibitor inobrodib in multiple myeloma today
Arun Swaminathan
CEO of Coya Therapeutics
Coya Therapeutics
Episode: Coya Therapeutics' CEO Arun Swaminathan discusses the company's focus on harnessing T-regs to treat neurodegenerative diseases
Leo Timashev
RBC Capital Markets biotech analyst
RBC Capital Markets
Episode: RBC Biotech Analyst Leo Timashev shares his take on the sector and discusses companies he covers that are in the news
Bo Cumo
President and CEO, Solid Biosciences
Solid Biosciences
Episode: Solid Biosciences CEO Bo Cumo discusses recent DMD data for the company's microdystrophin gene therapy, and explains the development and regulatory steps ahead
Christian Tidona
Founder and CEO of BioMedX
BioMedX
Episode: Christian Tidona's BioMed X and Michal Preminger are launching BioMed X Venture Labs in Cambridge, MA to create 'build to solve' startups with partners

Host

Brad
Host of Biotech TV, leading discussions with various biotech leaders and experts.

Chart Rankings

Talking Points

Recent interactions between the hosts and their guests.

Alloy Therapeutics announced a deal with Biogen today to help them discover antisense therapeutics using Alloy's ASO platform. Alloy Founder & CEO Errik Anderson fills us in at the company's R&D Day.
Q: With so many discovery options worldwide, why prioritize the United States and other regions, and how does Alloy decide where to conduct discovery?
Errik notes that Alloy serves as a global discovery service without its own pipeline, choosing sites to match partner preferences and emphasize high-quality, cutting-edge capabilities, including significant activity in the U.S., Europe, Japan, and ongoing expansion in the Middle East; decision-making is driven by client needs, technology readiness, and the aim to produce superior drug assets on a strong timeline.
Alloy Therapeutics announced a deal with Biogen today to help them discover antisense therapeutics using Alloy's ASO platform. Alloy Founder & CEO Errik Anderson fills us in at the company's R&D Day.
Q: Tell us what the ASO platform is and how you're helping Biogen and others with it.
Errik explains that the ASO platform is the anti-clastic antisense technology they've developed over years, partnering with Biogen to discover multiple targets; Alloy emphasizes high-quality, fast discovery with a focus on delivering assets suitable for progression to humans, and highlights the collaboration under Biogen's Jane Grogan and her Boston-based team.
Already this year Chai Discovery has raised a $130M series B and struck a discovery partnership with Eli Lilly - Co-Founder Jack Dent describes how Chai is using AI to design antibodies
Q: What in particular did you see in the biotech world that suggested an opportunity for AI from your previous work?
We identified two big shifts: first, that AI techniques like diffusion and language models were strong in other domains but hadn't yet cracked molecular design; second, a gap in engineering-fast, scalable systems in biotech that could support thousands of simultaneous experiments, moving us toward scalable, high-throughput AI-enabled discovery.
The new CEO of Stoke Therapeutics, Ian Smith, discusses Stoke Therapeutics' Dravet syndrome therapy, which caught much attention after publishing phase 1/2 data in NEJM last month
Q: What exactly are we seeing in the video of the little girl, and what is your therapy delivering to her and other patients?
The video shows a patient performing tasks and responding more normally after treatment, illustrating gains in motor function and social engagement. The therapy upregulates NAV1.1 via an ASO delivered intrathecally, aiming to reduce seizures and support neurotypical development, especially when started in early childhood.
Checking in with Menlo Ventures' Partner Greg Yap to get his take on the latest trends in AI in healthcare
Q: How is this playing out in term of investment and which areas look most promising for startups?
Investors are recognizing that small teams can deliver highly valued, personalized AI tools, while larger players are accelerating acquisitions and partnerships; the most promising areas include AI-enabled pharma R&D, personalized clinical tools, and efficient, umbrella-based regulatory and manufacturing strategies to scale rare-disease therapies.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About BiotechTV

What is BiotechTV about and what kind of topics does it cover?

Content focuses on cutting-edge advancements in biotechnology and healthcare, featuring insights from leading industry figures and discussing the latest innovations in drug development, treatment therapies, and biotech trends. Episodes frequently highlight significant biotechnology conferences, showcasing the perspectives of CEOs and experts on their respective companies and the broader industry landscape. A distinctive aspect is the emphasis on the intersection of technology and biotechnology, along with the incorporation of artificial intelligence in drug discovery and therapy development, which may appeal to listeners interested in the future of health and medical research. The content is ideal for professionals in the life sciences and ... more

Where can I find podcast stats for BiotechTV?

Rephonic provides a wide range of podcast stats for BiotechTV. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to BiotechTV and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does BiotechTV get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for BiotechTV, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for BiotechTV?

Rephonic provides comprehensive predictive audience data for BiotechTV, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does BiotechTV have?

To see how many followers or subscribers BiotechTV has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to BiotechTV?

These podcasts share a similar audience with BiotechTV:

1. Biotech Hangout
2. BioCentury This Week
3. The Readout Loud
4. The Long Run with Luke Timmerman
5. BioVenture VoiCes with Chris Garabedian

How many episodes of BiotechTV are there?

BiotechTV launched a year ago and published 426 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact BiotechTV?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for BiotechTV?

Rephonic pulls ratings and reviews for BiotechTV from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for BiotechTV?

Rephonic provides full transcripts for episodes of BiotechTV. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on BiotechTV?

Recent guests on BiotechTV include:

1. Errik Anderson
2. Ian Smith
3. Tom Miller
4. Jack Dent
5. Will West
6. Arun Swaminathan
7. Leo Timashev
8. Bo Cumo

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days